-
Our Vision is to improve healthcare as a global provider of innovative and reliable diagnostic tests. -
Our Mission is to identify and develop novel patentable diagnostic markers and technologies which can be commercialised to meet clinical needs, both in the laboratory and at the point of care. -
We will collaborate with partners, create branded products and identify complementary businesses which support our objective of continuing to grow as a respected and profitable healthcare company. -
Our Values include meeting all current and future regulatory, quality and environmental standards appropriate for our industry and the countries in which we operate.
Nycotest PT (INR)
The Nycotest PT-INR is a reagent used for screening of the extrinsic coagulation system with excellent sensitivity in the normal range. Its primary use is for control of oral anticoagulation therapy.
Test specific information
- Combined prothrombin time (PT) reagent
- Lyophilized reagent. Contains rabbit brain thromboplastin and adsorbed bovine plasma
- Sensitive to the depression of factors II, VII and X
- Insensitive to heparin in therapeutic doses
- ISI-value close to 1.0
- Capillary blood, citrated venous blood and citrated plasma can be used
- Can be measured on the Thrombotrack instruments
- Adaptability to automated coagulation instruments
- Kit size: 60 tests and 150 tests
- ISI Calibration Set available from Axis-Shield PoC
Clinical use of Nycotest PT
- For screening of the extrinsic coagulation system
- As a liver function test
- For control of oral anticoagulant therapy
*Products may not be approved for sale in all countries. Please contact your local distributor for further details.
Axis-Shield at a Glance
A pioneering organisation focused on the development and manufacturing of important and innovative in vitro diagnostic tests for use in clinical laboratories and at the point of care.
Focus on Afinion
Axis-Shield's award winning point-of-care test system is designed for maximum simplicity coupled with laboratory accuracy and reliability for a number of key markers important for improved patient management.
